GlaxoSmithKline (GSK)

[MinnieM]

GlaxoSmithKline plc (NYSE:GSK) has a significant global presence in over 150 countries, and it is a dividend-paying company with a huge pipeline of products.

In the Ebola space, it is working with research partners to develop a vaccine to prevent Ebola. GSK acquired the product when it purchased Okairos in May 2013. The GSK vaccine is called chimpanzee adenovirus Ebola.

The vaccine was evaluated in collaboration with the US National Institutes of Health's Vaccine Research Center, "VRC", before deciding to move forward with human safety trials.

An international consortium formed to fight the current Ebola outbreak has fast-tracked the vaccine, along with providing funding. The funding will also allow the manufacture of 10,000 additional doses to be ready, if the trials are successful.